{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:11:39Z","timestamp":1794525099973,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-51831-7","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T13:02:50Z","timestamp":1725886970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8580-8759","authenticated-orcid":false,"given":"Chun-Hua","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-510X","authenticated-orcid":false,"given":"Shang-Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0902-045X","authenticated-orcid":false,"given":"Cheng-I Daniel","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Heng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Yao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-3505","authenticated-orcid":false,"given":"Meng-Ru","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-8825","authenticated-orcid":false,"given":"Chun-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-4105","authenticated-orcid":false,"given":"Wu-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"51831_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736\u2013746 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"51831_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones, S. A. & Jenkins, B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18, 773\u2013789 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"51831_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.782","volume":"102","author":"S Rose-John","year":"2017","unstructured":"Rose-John, S. The soluble interleukin 6 receptor: advanced therapeutic options in inflammation. Clin. Pharmacol. Therapeut. 102, 591\u2013598 (2017).","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"51831_CR4","first-page":"4653","volume":"9","author":"M Trikha","year":"2003","unstructured":"Trikha, M., Corringham, R., Klein, B. & Rossi, J. F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9, 4653\u20134665 (2003).","journal-title":"Clin. Cancer Res."},{"key":"51831_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448\u2013457 (2015).","journal-title":"Nat. Immunol"},{"key":"51831_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers, C., Heink, S., Korn, T. & Rose-John, S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug Discov. 17, 395\u2013412 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"51831_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","volume":"50","author":"M Murakami","year":"2019","unstructured":"Murakami, M., Kamimura, D. & Hirano, T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity 50, 812\u2013831 (2019).","journal-title":"Immunity"},{"key":"51831_CR8","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-06-0861","volume":"12","author":"Z Duan","year":"2006","unstructured":"Duan, Z. et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 12, 5055\u20135063 (2006).","journal-title":"Clin. Cancer Res."},{"key":"51831_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-309","volume":"9","author":"WL Huang","year":"2010","unstructured":"Huang, W. L. et al. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol. Cancer 9, 309 (2010).","journal-title":"Mol. Cancer"},{"key":"51831_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207\u2013221 (2014).","journal-title":"Cancer Cell"},{"key":"51831_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1172\/JCI73531","volume":"124","author":"M Rokavec","year":"2014","unstructured":"Rokavec, M. et al. IL-6R\/STAT3\/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 124, 1853\u20131867 (2014).","journal-title":"J. Clin. Invest."},{"key":"51831_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","volume":"519","author":"K Taniguchi","year":"2015","unstructured":"Taniguchi, K. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519, 57\u201362 (2015).","journal-title":"Nature"},{"key":"51831_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"A Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga, A. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360\u2013371 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"51831_CR14","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500 (2004).","journal-title":"Science"},{"key":"51831_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"51831_CR16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","volume":"4","author":"GR Oxnard","year":"2018","unstructured":"Oxnard, G. R. et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 4, 1527\u20131534 (2018).","journal-title":"JAMA Oncol."},{"key":"51831_CR17","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","volume":"24","author":"Z Yang","year":"2018","unstructured":"Yang, Z. et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin. Cancer Res. 24, 3097\u20133107 (2018).","journal-title":"Clin. Cancer Res."},{"key":"51831_CR18","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).","journal-title":"Sci. Transl. Med."},{"key":"51831_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41568-021-00332-6","volume":"21","author":"AW Lambert","year":"2021","unstructured":"Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat. Rev. Cancer 21, 325\u2013338 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"51831_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41568-019-0213-x","volume":"19","author":"ED Williams","year":"2019","unstructured":"Williams, E. D., Gao, D., Redfern, A. & Thompson, E. W. Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nat. Rev. Cancer 19, 716\u2013732 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"51831_CR21","doi-asserted-by":"publisher","first-page":"15535","DOI":"10.1073\/pnas.1009472107","volume":"107","author":"Z Yao","year":"2010","unstructured":"Yao, Z. et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl Acad. Sci. USA 107, 15535\u201315540 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"51831_CR22","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1158\/1535-7163.MCT-12-0311","volume":"11","author":"SM Kim","year":"2012","unstructured":"Kim, S. M. et al. Activation of IL-6R\/JAK1\/STAT signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer Ther. 11, 2254\u20132264 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"51831_CR23","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-10-2743","volume":"17","author":"H Korkaya","year":"2011","unstructured":"Korkaya, H., Liu, S. & Wicha, M. S. Regulation of cancer stem cells by cytokine networks: attacking cancer\u2019s inflammatory roots. Clin. Cancer Res. 17, 6125\u20136129 (2011).","journal-title":"Clin. Cancer Res."},{"key":"51831_CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fmolb.2020.00063","volume":"7","author":"VernotJP Senescence-Associated Pro-inflammat","year":"2020","unstructured":"Senescence-Associated Pro-inflammatory Cytokines, VernotJ. P. and tumor cell plasticity. Front. Mol. Biosci. 7, 63 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"51831_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104\u2013122.e112 (2020).","journal-title":"Cancer Cell"},{"key":"51831_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2016.09.001","volume":"30","author":"G Ferone","year":"2016","unstructured":"Ferone, G. et al. SOX2 is the determining oncogenic switch in promoting lung squamous cell carcinoma from different cells of origin. Cancer Cell 30, 519\u2013532 (2016).","journal-title":"Cancer Cell"},{"key":"51831_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi, S. & de Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39\u201356 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"51831_CR28","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1126\/science.aaf4445","volume":"354","author":"L Mosteiro","year":"2016","unstructured":"Mosteiro, L. et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science 354, 6315 (2016).","journal-title":"Science"},{"key":"51831_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/stem.1993","volume":"33","author":"N Bora-Singhal","year":"2015","unstructured":"Bora-Singhal, N. et al. YAP1 regulates OCT4 activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells. Stem cells 33, 1705\u20131718 (2015).","journal-title":"Stem cells"},{"key":"51831_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/j.1460-2075.1987.tb02357.x","volume":"6","author":"P Poupart","year":"1987","unstructured":"Poupart, P. et al. B cell growth modulating and differentiating activity of recombinant human 26-kd protein (BSF-2, HuIFN-beta 2, HPGF). EMBO J 6, 1219\u20131224 (1987).","journal-title":"EMBO J"},{"key":"51831_CR31","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/S0006-291X(88)80404-2","volume":"152","author":"LT May","year":"1988","unstructured":"May, L. T. et al. Phosphorylation of secreted forms of human beta 2-interferon\/hepatocyte stimulating factor\/interleukin-6. Biochem. Biophys. Res. Commun. 152, 1144\u20131150 (1988).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"51831_CR32","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1073\/pnas.82.16.5490","volume":"82","author":"T Hirano","year":"1985","unstructured":"Hirano, T. et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc. Natl Acad. Sci. USA 82, 5490\u20135494 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"51831_CR33","doi-asserted-by":"publisher","first-page":"9950","DOI":"10.1016\/S0021-9258(18)92911-X","volume":"266","author":"LT May","year":"1991","unstructured":"May, L. T., Santhanam, U. & Sehgal, P. B. On the multimeric nature of natural human interleukin-6. J. Biol. Chem. 266, 9950\u20139955 (1991).","journal-title":"J. Biol. Chem."},{"key":"51831_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ccell.2019.06.006","volume":"36","author":"S Mereiter","year":"2019","unstructured":"Mereiter, S., Balmana, M., Campos, D., Gomes, J. & Reis, C. A. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell 36, 6\u201316 (2019).","journal-title":"Cancer Cell"},{"key":"51831_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1432-1033.1992.tb19838.x","volume":"203","author":"RB Parekh","year":"1992","unstructured":"Parekh, R. B., Dwek, R. A., Rademacher, T. W., Opdenakker, G. & Van Damme, J. Glycosylation of interleukin-6 purified from normal human blood mononuclear cells. Eur. J. Biochem. 203, 135\u2013141 (1992).","journal-title":"Eur. J. Biochem."},{"key":"51831_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1084\/jem.20031205","volume":"199","author":"CS Dela Cruz","year":"2004","unstructured":"Dela Cruz, C. S. et al. N-linked glycosylation is required for optimal function of Kaposi\u2019s sarcoma herpesvirus-encoded, but not cellular, interleukin 6. J. Exp. Med. 199, 503\u2013514 (2004).","journal-title":"J. Exp. Med."},{"key":"51831_CR37","doi-asserted-by":"publisher","first-page":"188464","DOI":"10.1016\/j.bbcan.2020.188464","volume":"1875","author":"D Thomas","year":"2021","unstructured":"Thomas, D., Rathinavel, A. K. & Radhakrishnan, P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochimica. et biophysica. Acta Rev. Cancer 1875, 188464 (2021).","journal-title":"Biochimica. et biophysica. Acta Rev. Cancer"},{"key":"51831_CR38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15, 540\u2013555 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"51831_CR39","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1038\/sj.onc.1209464","volume":"25","author":"HH Yeh","year":"2006","unstructured":"Yeh, H. H., Lai, W. W., Chen, H. H., Liu, H. S. & Su, W. C. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25, 4300\u20134309 (2006).","journal-title":"Oncogene"},{"key":"51831_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1021\/cr000423j","volume":"102","author":"J Roth","year":"2002","unstructured":"Roth, J. Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. Chem. Rev. 102, 285\u2013303 (2002).","journal-title":"Chem. Rev."},{"key":"51831_CR41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.tcb.2015.12.004","volume":"26","author":"F Bard","year":"2016","unstructured":"Bard, F. & Chia, J. Cracking the glycome encoder: signaling, trafficking, and glycosylation. Trends Cell Biol. 26, 379\u2013388 (2016).","journal-title":"Trends Cell Biol."},{"key":"51831_CR42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","volume":"21","author":"KT Schjoldager","year":"2020","unstructured":"Schjoldager, K. T., Narimatsu, Y., Joshi, H. J. & Clausen, H. Global view of human protein glycosylation pathways and functions. Nat. Rev. Mol. Cell Biol. 21, 729\u2013749 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"51831_CR43","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"51831_CR44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"51831_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/0008-5472.CAN-11-1403","volume":"72","author":"H Okayama","year":"2012","unstructured":"Okayama, H. et al. Identification of genes upregulated in ALK-positive and EGFR\/KRAS\/ALK-negative lung adenocarcinomas. Cancer Res. 72, 100\u2013111 (2012).","journal-title":"Cancer Res."},{"key":"51831_CR46","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nchembio.2194","volume":"12","author":"C Lopez-Sambrooks","year":"2016","unstructured":"Lopez-Sambrooks, C. et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat. Chem. Biol. 12, 1023\u20131030 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"51831_CR47","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/pmic.200300771","volume":"4","author":"N Blom","year":"2004","unstructured":"Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S. & Brunak, S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4, 1633\u20131649 (2004).","journal-title":"Proteomics"},{"key":"51831_CR48","doi-asserted-by":"publisher","first-page":"20434","DOI":"10.1016\/S0021-9258(18)54942-5","volume":"266","author":"K Yamaguchi","year":"1991","unstructured":"Yamaguchi, K. et al. Effects of site-directed removal of N-glycosylation sites in human erythropoietin on its production and biological properties. J. Biol. Chem. 266, 20434\u201320439 (1991).","journal-title":"J. Biol. Chem"},{"key":"51831_CR49","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1111\/febs.12800","volume":"281","author":"R Bobby","year":"2014","unstructured":"Bobby, R. et al. Functional implications of large backbone amplitude motions of the glycoprotein 130-binding epitope of interleukin-6. FEBS J. 281, 2471\u20132483 (2014).","journal-title":"FEBS J."},{"key":"51831_CR50","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1074\/jbc.M111.295964","volume":"287","author":"H Xiong","year":"2012","unstructured":"Xiong, H. et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem. 287, 5819\u20135832 (2012).","journal-title":"J. Biol. Chem."},{"key":"51831_CR51","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1002\/stem.1752","volume":"32","author":"W Wei","year":"2014","unstructured":"Wei, W. et al. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem cells 32, 2571\u20132582 (2014).","journal-title":"Stem cells"},{"key":"51831_CR52","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/stem.2320","volume":"34","author":"C Yao","year":"2016","unstructured":"Yao, C. et al. IGF\/STAT3\/NANOG\/Slug signaling axis simultaneously controls epithelial-mesenchymal transition and stemness maintenance in colorectal cancer. Stem Cells 34, 820\u2013831 (2016).","journal-title":"Stem Cells"},{"key":"51831_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/CMR.0000000000000021","volume":"23","author":"YR Na","year":"2013","unstructured":"Na, Y. R., Lee, J. S., Lee, S. J. & Seok, S. H. Interleukin-6-induced twist and N-cadherin enhance melanoma cell metastasis. Melanoma Res. 23, 434\u2013443 (2013).","journal-title":"Melanoma Res."},{"key":"51831_CR54","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.jid.5700109","volume":"126","author":"RM Gallucci","year":"2006","unstructured":"Gallucci, R. M., Lee, E. G. & Tomasek, J. J. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J. Invest. Dermatol. 126, 561\u2013568 (2006).","journal-title":"J. Invest. Dermatol"},{"key":"51831_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.celrep.2019.11.115","volume":"30","author":"M Romera-Hernandez","year":"2020","unstructured":"Romera-Hernandez, M. et al. Yap1-driven intestinal repair is controlled by group 3 innate lymphoid cells. Cell Rep. 30, 37\u201345.e33 (2020).","journal-title":"Cell Rep."},{"key":"51831_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13771-5","volume":"11","author":"T Tsuji","year":"2020","unstructured":"Tsuji, T. et al. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat. Commun. 11, 74 (2020).","journal-title":"Nat. Commun."},{"key":"51831_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33190-8","volume":"8","author":"A Takahashi","year":"2018","unstructured":"Takahashi, A. et al. Ankyrin repeat domain 1 overexpression is associated with common resistance to afatinib and osimertinib in EGFR-mutant lung cancer. Sci. Rep. 8, 14896 (2018).","journal-title":"Sci. Rep."},{"key":"51831_CR58","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genom. Proteom. Bioinform. 20, 587\u2013596 (2022).","journal-title":"Genom. Proteom. Bioinform."},{"key":"51831_CR59","first-page":"10007","volume":"1","author":"N Roper","year":"2020","unstructured":"Roper, N. et al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep. Med. 1, 10007 (2020).","journal-title":"Cell Rep. Med."},{"key":"51831_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"51831_CR61","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-21-0933","volume":"82","author":"MC Heinz","year":"2022","unstructured":"Heinz, M. C. et al. Liver colonization by colorectal cancer metastases requires YAP-controlled plasticity at the micrometastatic stage. Cancer Res. 82, 1953\u20131968 (2022).","journal-title":"Cancer Res."},{"key":"51831_CR62","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1158\/0008-5472.CAN-18-3376","volume":"79","author":"N Hamanaka","year":"2019","unstructured":"Hamanaka, N. et al. YES1 is a targetable oncogene in cancers harboring YES1 gene amplification. Cancer Res. 79, 5734\u20135745 (2019).","journal-title":"Cancer Res."},{"key":"51831_CR63","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1158\/0008-5472.CAN-18-0505","volume":"78","author":"C Lopez Sambrooks","year":"2018","unstructured":"Lopez Sambrooks, C. et al. Oligosaccharyltransferase inhibition overcomes therapeutic resistance to EGFR tyrosine kinase inhibitors. Cancer Res. 78, 5094\u20135106 (2018).","journal-title":"Cancer Res."},{"key":"51831_CR64","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1172\/JCI126022","volume":"129","author":"LC Chan","year":"2019","unstructured":"Chan, L. C. et al. IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J. Clin. Invest. 129, 3324\u20133338 (2019).","journal-title":"J. Clin. Invest."},{"key":"51831_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0416-z","volume":"14","author":"MR Miller","year":"2015","unstructured":"Miller, M. R. et al. Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma. Mol. Cancer 14, 141 (2015).","journal-title":"Mol. Cancer"},{"key":"51831_CR66","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/bjc.2016.116","volume":"114","author":"S Chugh","year":"2016","unstructured":"Chugh, S., Meza, J., Sheinin, Y. M., Ponnusamy, M. P. & Batra, S. K. Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation. Br. J. Cancer 114, 1376\u20131386 (2016).","journal-title":"Br. J. Cancer"},{"key":"51831_CR67","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.molcel.2017.10.010","volume":"68","author":"C Peng","year":"2017","unstructured":"Peng, C. et al. Regulation of the Hippo-YAP pathway by glucose sensor O-GlcNAcylation. Mol. Cell 68, 591\u2013604.e595 (2017).","journal-title":"Mol. Cell"},{"key":"51831_CR68","first-page":"2605","volume":"9","author":"TL Hung","year":"2003","unstructured":"Hung, T. L. et al. Clinical evaluation of HER-2\/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. Clin. Cancer Res. 9, 2605\u20132612 (2003).","journal-title":"Clin. Cancer Res."},{"key":"51831_CR69","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1165\/ajrcmb.17.3.2837","volume":"17","author":"YW Chu","year":"1997","unstructured":"Chu, Y. W. et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol. 17, 353\u2013360 (1997).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"51831_CR70","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"JR Wisniewski","year":"2009","unstructured":"Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359\u2013362 (2009).","journal-title":"Nat. Methods"},{"key":"51831_CR71","first-page":"13 20 11","volume":"13","author":"M Bern","year":"2012","unstructured":"Bern, M., Kil, Y. J. & Becker, C. Byonic: advanced peptide and protein identification software. Curr. Protocol. Bioinform. 13, 13 20 11\u201313 20 14 (2012).","journal-title":"Curr. Protocol. Bioinform."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51831-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51831-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51831-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:02:36Z","timestamp":1786708956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51831-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51831"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51831-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"25 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of Supplementary Information initially published alongside this article, Supplementary Tables 1\u20133 were missing, and are now available in the HTML version of the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7885"}}